Teplizumab (Tzield, Sanofi) may delay the onset of type 1 diabetes (T1D), but barriers to treatment may affect adherence to the medication. Increased screening opportunities and education about these programs …
Tag:
teplizumab
-
Type 1
-
1. In this randomized controlled trial, two 12-day courses of teplizumab improved C-peptide levels compared to placebo at week 78 in patients with stage 3 type 1 diabetes. 2. No …